Padovan I, Brodarec I, Ikić D, Knezević M, Soos E
J Cancer Res Clin Oncol. 1981;100(3):295-310. doi: 10.1007/BF00410690.
The clinical experimental model of HLI application in the therapy of skin and mucosal cancers of the head and neck has opened new prospects in HLI utilization. Based on clinical observations and research it may be concluded that HLI, if applied topically in the area of the tumor, may induce its disappearance or regression. If applied presurgically, it blocks the dispersion of neocytes during surgery. Also, HLI inhibits metastatic dissemination of malignant tumors and therefore might reduce the percentage of patients with recurrence, decreasing the chance of survival of any other primary tumor.
高剂量光免疫疗法(HLI)应用于头颈部皮肤和黏膜癌治疗的临床实验模型为HLI的利用开辟了新前景。基于临床观察和研究可以得出结论,HLI如果局部应用于肿瘤区域,可能会使其消失或缩小。如果在手术前应用,它会在手术过程中阻止新生细胞的扩散。此外,HLI可抑制恶性肿瘤的转移扩散,因此可能会降低复发患者的比例,减少其他原发肿瘤的生存几率。